Background: Conventional imaging modalities are inadequate to evaluate locoregional extension of prostate cancer (PCa). The aim of the current retrospective study was to investigate the diagnostic efficacy of Gallium-68 prostate-specific membrane antigen-11 (Ga-68 PSMA-11) positron emission tomography/computed tomography (PET/CT) and multiparametric magnetic resonance imaging (mp-MRI) for staging preoperative PCa patients with correlating histopathology.

Materials And Methods: Twenty-four patients with histologically proven PCa underwent both Ga-68 PSMA-11 PET/CT and mp-MRI before robot-assisted laparoscopic radical prostatectomy. For each tumor area, correlations with histopathological results were defined for tumor localization, extraprostatic extension (EPE) of the tumor, invasion of seminal vesicle (SVI) and bladder neck invasion (BNI). In patients with regional lymph node (LN) dissection, histopathological results were also correlated with imaging modalities.

Results: Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for detection of EPE and SVI were higher for mp-MRI than Ga-68 PSMA-11 PET/CT. On the other hand Ga-68 PSMA-11 PET/CT had significant successful results for detection of LN metastases when compared with mp-MRI. But for BNI detection both modalities had same insufficient results. Ga-68 PSMA-11 PET/CT had strong results for appropriate tumor localization in the gland.

Conclusion: Ga-68 PSMA PET/CT has superior results for assessing local LN metastases and for intraprostatic tumor localization. Whereas, mp-MRI must be the preferred modality for determining SVI and EPE. But both imaging modalities failed for determining BNI accurately. Both modalities should be used in conjunction with each other for better treatment planning.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23812DOI Listing

Publication Analysis

Top Keywords

ga-68 psma-11
24
psma-11 pet/ct
16
tumor localization
12
prostate cancer
8
imaging modalities
8
ga-68
7
psma-11
6
mp-mri
6
pet/ct
6
tumor
5

Similar Publications

PET/CT targeting prostate-specific membrane antigen (PSMA) is commonly used in patients with prostate cancer. PSMA has been found in other solid tumours, including primary brain tumours. The aim of this study was to evaluate the usefulness of [Ga]Ga-PSMA-11 PET/CT for preoperative diagnosis and 2-year prognosis.

View Article and Find Full Text PDF

Purpose: This study evaluated interlesion heterogeneity in prostate cancer using dual-tracer imaging (PSMA and FDG) and explored its predictive value for novel hormone therapy (NHT).

Patients And Methods: A total of 205 prostate cancer patients (23 biochemical recurrences, 68 metastatic castration-sensitive prostate cancers, 114 metastatic castration-resistant prostate cancers [mCRPC]) who underwent dual 18 F-FDG and 68 Ga-PSMA PET/CT imaging were retrospectively analyzed. Among them, 62 mCRPC patients received NHT.

View Article and Find Full Text PDF

Second primary malignancies are being increasingly detected in the setting of thyroid cancer, because of adoption of the advanced imaging modalities including PET/CT. Herein, we present a patient of papillary thyroid carcinoma who initially underwent total thyroidectomy with bilateral neck dissection followed by 131 I radioactive iodine therapy. A prostatic lesion was incidentally detected on 18 F-FDG PET/CT scan, which was intensely 18 F-FDG avid and also showed intense focal 68 Ga-prostate-specific membrane antigen (PSMA) uptake on 68 Ga-PSMA-11 PET/CT scan.

View Article and Find Full Text PDF

[Clinical Value of Dual Tracer PET Imaging With Ga-PSMA and F-FDG in Patients With Metastatic Prostate Cancer].

Sichuan Da Xue Xue Bao Yi Xue Ban

September 2024

( 610041) Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.

Objective: In this study, we retrospectively analyzed the imaging characteristics of dual-tracer Ga-prostate specific membrane antigen (PSMA) and F-flurodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in metastatic prostate cancer (mPCa) patients. We analyzed the uptake modes of the dual tracers, explored clinical pathological parameters affecting the F-FDG uptake in the lesions, and evaluated their prognostic implications for prostate specific antigen progression-free survival (PSA-PFS).

Methods: A total of 41 mPCa patients who underwent dual-tracer PET/CT (Ga-PSMA and F-FDG) scans between September 2021 and January 2024 were retrospectively enrolled.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the feasibility and short-term outcomes of a new treatment for prostate cancer recurrence called PSMA radioguided salvage pelvic lymph node dissection (S-PLND), which helps detect and remove cancerous lymph nodes using advanced imaging techniques.
  • In a group of 14 patients, results showed that the majority (93%) had successful detection and removal of cancerous targets, and there were no complications from the procedure, indicating its safety.
  • Although some patients experienced a decline in prostate-specific antigen (PSA) levels after surgery, further research is needed to refine patient selection and understand the long-term clinical benefits of this treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!